Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Multi-Gene Panel Testing Catches Cancer Risk Variants

By LabMedica International staff writers
Posted on 25 Apr 2019
Over 608,000 patients with ovarian, breast, pancreatic, prostate and colorectal cancer are diagnosed each year. Current guidelines recommend testing all patients with ovarian and pancreatic cancer, as well as patients with prostate, breast and colorectal cancer (CRC) who meet certain criteria.

However such guidelines say little about the role of expanded multi-gene panel testing in these patients. Studies have begun to show that germline testing using comprehensive multi-gene panels identifies clinically actionable mutations in genes other than those recommended per the patient’s cancer type, at a very modest incremental cost of uncovering these additional mutations.

A team of scientists collaborating with the genetic testing company Invitae (San Francisco, CA, USA) analyzed de-identified sequence data for 83 cancer-risk genes in patients with 81,861 breast, 11,124 ovarian, 9,669 CRC, 5,794 prostate, and 4,659 pancreatic cancer referred for hereditary cancer genetic testing. These genes were assessed uniformly for all patients in this study, regardless of the specific genes ordered by clinicians based on personal/family history.

The team compared the positive rate for each cancer type, where a positive report was defined by the presence of a likely pathogenic (LP) or pathogenic (P) variant. Positive rates for a minimal gene panel for the respective indication (e.g. BRCA1/2 or the five Lynch Syndrome [LS] genes) were computed and compared to the positive rates when the comprehensive 83 gene panel was analyzed.

When the Invitae Multi-Cancer 83-gene comprehensive panel was applied, the overall diagnostic yield for all 113,107 patients with breast, ovarian, pancreatic, prostate and CRC increased almost 4-fold to 16%. Excluding mono-allelic P/LP variants in predominantly recessive cancer-risk genes (e.g. MUTYH) reduces the diagnostic yield to 13%. Stratified by cancer type, and removing mono-allelic recessives, positive yield was: breast 11.8%, ovarian 18%, prostate 15%, pancreatic 16% and CRC 19%.

The authors concluded that their study suggests that genetic testing guidelines should be expanded to include clear recommendations supporting multi-gene panel testing in patients with cancer, to improve the care of patients and their family members. Robert Nussbaum, MD, Invitae's chief medical officer, said, “Genetic test panels that include just a few of the clinically important genes provide incomplete genetic information for patients and their clinicians, both in terms of informing treatment choices and identifying additional health risks. The study was presented at the American College of Medical Genetics and Genomics annual meeting held April 2-6, 2019, in Seattle, WA, USA.

Related Links:
Invitae


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Auto Clinical Chemistry Analyzer
cobas c 703
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.